Work

Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208

Year: 2018

Type: article

Abstract: Introduction: While both anti-VEGF(R) and EGFR antibodies have activity in metastatic RAS wild type CRC, the combination of the two appeared to be detrimental when combined with chemotherapy in unselected CRC patients. We undertook this study to determine whether the anti-VEGFR antibody, ramucirumab, improved activity of Irinotecan and Cetuximab as 2nd line therapy in KRASwt CRC patients, who previously received FOLFOX or CAPOX with bevacizumab (bev) first line therapy, and were now progressing.

Source: Annals of Oncology

DOI: 10.1093/annonc/mdy149.029

Authors: H. Hochster, Paul J. Catalano, Peter J. O'Dwyer, Edith P. Mitchell, Deirdre Jill Cohen, Bryan Andrew Faller, Jeremy S. Kortmansky, Sheetal Mehta Kircher, Jill Lacy, Heinz-Josef Lenz, Udit N. Verma, Al Bowen Benson

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $5,080

OpenAlex ID: W2808961664

FWCI:

Cites:

Cited by:

Related to: 10